Background {#Sec1}
==========

In a case--control genome-wide association study (GWAS), to detect the associated single-nucleotide polymorphisms (SNPs), we need to conduct a test for each individual SNP data, which are summarized as a 2-by-3 table. Although Pearson's chi-square test can be used, it is usually less powerful than the Cochran-Armitage trend test (CATT) if the genetic model is known \[[@CR1]--[@CR3]\]. However, if the genetic models are unknown or various, the optimal scores in the CATTs are difficult or unable to find. If we use a CATT with fixed scores for all SNPs, we may lose power for some situations \[[@CR4]--[@CR13]\]. To circumvent this disadvantage, in the literature, many robust association tests have been proposed \[[@CR7], [@CR12], [@CR14]--[@CR22]\]. Those tests do not rely solely on one specific genetic model; rather they consider several possible genetic models simultaneously. In addition, many of them are based on the assumption that the underlying genetic model is one of the following three: additive, recessive, and dominant. For example, the maxmin efficiency robust test (MERT) by Gastwirth \[[@CR23], [@CR24]\], and the maximum of the three optimal CATTs under recessive, additive, and dominant models (MAX3) have been studied \[[@CR6]\]. Zheng and Ng proposed a two-phase procedure called genetic model selection (GMS) method \[[@CR12]\] which selects a genetic model from the three models in its first stage. On the contrary, Joo et al. proposed a test which eliminates genetic models \[[@CR25]\]. Due to the environmental interaction, there are unlimited genetic models besides the three ideal models (recessive, additive, and dominant). Chen and Ng proposed a robust association test based on the generalized genetic model (GGM) \[[@CR19]\], which includes the recessive, additive, and dominant models as special cases. Their approach obtains a p-value from a one-sided test for each of the two possible disease alleles. With the uncertainty of the disease allele, the overall p-value is then approximated from the two dependent tests.

In this paper, we propose a new robust association test which utilizes the GGM and obtains a one-sided p-value based on the selected disease allele. The performance of the new test is compared with existing methods in terms of controlling type I error rate and detecting power. Some real data applications are also used to demonstrate the use of the new test.

Methods {#Sec2}
=======

GGM and existing methods {#Sec3}
------------------------

The data of a diallelic SNP with alleles *A* and *a* in a case control GWAS are summarized in Table [1](#Tab1){ref-type="table"}, where r~1~, r~2~, and r~3~ are the frequencies of genotypes *AA, Aa,* and *aa*, respectively, for the r cases; and s~1~, s~2~, and s~3~ are the frequencies of genotypes *AA*, *Aa*, and *aa*, respectively, for the s controls.Table 1**SNP data in a case control GWAS**Genotype***AA**Aa**aa***TotalCase*r* ~*1*~*r* ~*2*~*r* ~*3*~*r*Control*s* ~*1*~*s* ~*2*~*s* ~*3*~*s*Total*n* ~*1*~*n* ~*2*~*n* ~*3*~*n*

Among the three genotypes *AA, Aa*, and *aa*, the relative risks of genotypes *Aa* and *aa* to *AA* are defined as:

Under the null hypothesis that there is no association between the genotype and phenotype, we have Λ~1~ = Λ~2~ = 1. Regarding the alternative hypothesis, we assume the underlying genetic model is a GGM, which is also called order-restricted relative risks model \[[@CR19]\]. For the case where *a* is the disease allele, GGM assumes Λ~1~ ≥ 1 and Λ~2~ ≥ Λ~1~ with at least one of the inequalities is strictly greater than. It is easy to see that the aforementioned ideal models, recessive (Λ~1~ = 1, Λ~2~ \> Λ~1~), additive (Λ~1~ = (1 + Λ~2~)/2), and dominant (Λ~1~ = Λ~2~ \> 1), are all special cases of the generalized model. If *A,* rather *a,* is the disease allele, GGM assumes 1 ≥ Λ~1~ and Λ~1~ ≥ Λ~2~ with at least one of the inequalities is strict.

Suppose the frequencies for *AA, Aa*, and *aa* are *p*~*1*~*, p*~*2*~*, p*~*3*~ for cases and *q*~*1*~*, q*~*2*~, and *q*~*3*~ for controls, respectively. Under the null hypothesis that there is no association between the disease and the genotype, it is easy to show *p*~*1*~  *= q*~*1*~, *p*~*2*~  *= q*~*2*~, and *p*~*3*~  *= q*~*3*~. In this paper, we assume the cases and controls follow trinomial distributions TN(r, *p*~*1*~*, p*~*2*~*, p*~*3*~) and TN (s, *q*~*1*~*, q*~*2*~*, q*~*3*~), respectively.

The test statistics for some well-known existing methods are summarized as follows:

The CATT test statistic is \[[@CR8]\]:

They are the scores assigned to the three columns.

The statistic for MAX3 is \[[@CR6]\]:

The statistic for GMS is \[[@CR12], [@CR13]\]:

where *I* is the indicator function, and the Hardy-Weinberg disequilibrium trend test (HWDTT) statistic is given by \[[@CR15]\]:

and *c* is a constant and usually chosen as 1.645. Here n~i~ = s~i~ + r~i~ (i = 1,2,3), and n = n~1~ + n~2~ + n~3~.

The statistic for MERT is \[[@CR24]\]:

The proposed test {#Sec4}
-----------------

Let , it can be shown that under the null hypothesis of no association, the mean of the vector *E*\[*T*\] = 0, and variance-covariance matrix is.

We define the following "standardized" statistics:

It is easy to prove the following result.

**Theorem 1.** Asymptotically, under the null hypothesis the statistics in (2) follow a multivariate normal distribution, *Z* \~ *MVN* (0, Σ~*Z*~), where the variance-covariance matrix is.

From theorem 1,  *Z*~1~, *Z*~2~ and *Z*~3~ are linear dependent; it is not difficult to show that asymptotically  *Z*~3~ = *aZ*~1~ + *bZ*~2~, where , and . It can also be shown that under the GGM, if *a* (or *A*) is the disease allele, the expectations of Z~i~ (i = 1,2,3) in (2) are all greater (or less) than 0. In addition, under the GGM, if z~1~ is close to 0, the genetic model is close to the recessive model. On the other hand, the genetic model is unlikely to be the recessive model if z~1~ is far from 0.

We will select the disease allele based on the sign of Z~3~, and combine the two one-sided p-values obtained based on the selected disease allele. Following the idea of combining p-values from independent studies using robust test \[[@CR26]\], we define the test statistic as follows:

where Φ(∙) is the cumulative density function (CDF) of the standard normal distribution (N(0,1)) and F^- 1^(∙) is the inverse of the CDF of the chi-square distribution with one degree of freedom.

Usually it is difficult to directly calculate the p-value (or critical value) for statistic C in (3). However, the p-value can be easily estimated using resampling method. Specifically, we first simulate two independent samples, z~1~, and z~2~, both from N(0,1). Then we calculate , where , are the estimates of *a* and *b*, and are the estimates for *p*~*i*~ (*i* = 1, 2, 3) from the data. Next we calculate.

. We repeat the above steps K times and get K values for g. The p-value can then be estimated as (*number of g* \' *s that are greater than or equal to c*)/*K*, where c is the observed statistic calculated from data using (3).

Results and discussion {#Sec5}
======================

Simulation study {#Sec6}
----------------

In this section, we will assess the performance of the proposed test by comparing it with existing methods in terms of controlling type I error rate and detecting power through a comprehensive simulation study. In the simulation study we assume that cases and controls in Table [1](#Tab1){ref-type="table"} follow trinomial distributions with probabilities *p = (p*~*1*~*,p*~*2*~*,p*~*3*~*)* and *q = (q*~*1*~*,q*~*2*~*,q*~*3*~*)*, respectively. It can be shown that, for given *q*~*i*~'s, and relative risks Λ~1~, Λ~2~, the values of the corresponding *p*~*i*~'s can be obtained as follows \[[@CR17]--[@CR21]\]: , , and .

We first assume Hardy--Weinberg equilibrium (HWE) holds for controls, and the minor allele frequencies (MAF) are 0.3 and 0.5. The disease allele is either the minor or the major allele. The numbers of cases (*r*) and controls (*s*) are both set to be 1000. Different pairs of *Λ*~1~ and *Λ*~2~ are used in the simulation to compare the performance of our proposed method with those of GMS, MERT, MAX3, Pearson's chi-square test, and CATT with *x* = 0.5, which is the commonly used test under the assumption of additive genetic model. More specifically, we fix *Λ*~2~ to be 1.4 and let *Λ*~1~ vary from 1.0 to 1.4 with increment 0.1. Therefore, the three special genetic models are included in the simulation study. To assess the robustness of the proposed test, we also simulate data from genetic models other than the GGM: over-dominant model (*Λ*~1~ = 1.5, *Λ*~2~ = 1.4 ) and under-dominant model (*Λ*~1~ = 0.9, *Λ*~2~ = 1.4). The significance level is set to be 0.05, and the type I error rate and power are estimated by the proportions of rejections from 1000 replicates. To estimate the p-value for the proposed test, we resample 10,000 times (i.e., K = 10,000). The p-values from MAX3, GMS, and MERT are obtained by using the R package "Rassoc" \[[@CR13]\].

When the null hypothesis is true (*Λ*~1~ = *Λ*~2~ = 1), all methods have rejection proportions close to the preset significance level 0.05 (For power values, see Additional file [1](#MOESM1){ref-type="media"}: Power plots of Figures S1-S5 for Tables 2-6); this indicates that they can control type I error rate. Table [2](#Tab2){ref-type="table"} reports the empirical powers of each method when HWE holds for controls with MAF equals to 0.3, and the minor allele is the risk allele. The chi-square test is usually less powerful than the proposed test except for the condition where the genetic model is over-dominant, under which the proposed test is more powerful than other methods. The CATT and MERT perform relatively poorly when the genetic models are far from the additive model. MAX3 and GMS perform similarly and have comparable power values with the proposed test; while the new test performs better when the genetic model is dominant or over-dominant. Table [3](#Tab3){ref-type="table"} lists the power values when HWE holds for controls with MAF equals to 0.3, and the major allele is the risk allele. Once again, the CATT and MERT lose power dramatically compared to other methods when the genetic model is recessive or under-dominant. The proposed test is more powerful than the MAX3 and GMS when the genetic models are close to recessive model. The chi-square test is less powerful than the proposed test when the genetic models are between recessive and dominant.Table 2**Empirical type I error rates and powers for each method from 1000 replicates at significance level 0.05 when the sample sizes are 1000 for cases and controls and HWE holds for controls with minor allele is the disease allele and MAF equals 0.3*Λ*** ~1~ ***Λ*** ~2~(1,1)(1, 1.4) RM\*(1.1, 1.4)(1.2, 1.4) AM\*(1.3, 1.4)(1.4, 1.4) DM\*(1.5,1.4) ODM\*(0.9, 1.4) UDM\*ChiSQ0.0530.9270.7590.5280.3950.4280.5240.992MAX30.0510.9410.7940.5680.4380.4450.4840.994GMS0.050.9330.7720.5770.4310.4320.4590.993CATT0.050.9340.8070.6440.4270.250.1360.986MERT0.0510.8790.7440.6420.4790.3770.2610.938GGM0.0530.9440.7930.5980.4470.4320.4120.995New0.0490.9270.7610.5740.4550.460.5120.982\**RM*: Recessive Model; *AM*: Additive Model; *DM*: Dominant Model; *ODM*: Over-dominant Model; *UDM*: Under-dominant Model.Table 3**Empirical type I error rates and powers for each method from 1000 replicates at significance level 0.05 when the sample sizes are 1000 for cases and controls and HWE holds for controls with major allele is the disease allele and MAF equals 0.3*Λ*** ~1~ ***Λ*** ~2~(1,1)(1, 1.4) RM\*(1.1, 1.4)(1.2, 1.4) AM\*(1.3, 1.4)(1.4, 1.4) DM\*(1.5,1.4) ODM\*(0.9, 1.4) UDM\*ChiSQ0.0460.5380.4960.6150.8050.9330.9880.752MAX30.0480.5520.5470.6620.8310.9480.9870.676GMS0.050.5470.5360.6480.8270.9330.9860.681CATT0.0480.3750.5550.7160.8540.9260.9630.195MERT0.0420.450.5870.6850.8110.8530.9110.324GGM0.0520.5230.550.6820.8390.9440.9870.614New0.0500.5260.5510.6780.8390.9420.9710.602\**RM*: Recessive Model; *AM*: Additive Model; *DM*: Dominant Model; *ODM*: Over-dominant Model; *UDM*: Under-dominant Model.

Table [4](#Tab4){ref-type="table"} gives the empirical powers when HWE holds for controls with MAF equals to 0.5. As seen in Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}, the CATT and MERT are less powerful when the genetic model is dominant or over-dominant. On the contrary, chi-square test is reasonably powerful under those situations. The proposed test has the largest powers when the genetic model is close to the dominant one (i.e.,  *Λ*~1~ = 1.3, 1.4, 1.5). For other situations, the new test has comparable powers with those from MAX3 and GMS.Table 4**Empirical type I error rates and powers for each method from 1000 replicates at significance level 0.05 when the sample sizes are 1000 for cases and controls and HWE holds for controls MAF equals 0.5*Λ*** ~1~ ***Λ*** ~2~(1,1)(1, 1.4) RM\*(1.1, 1.4)(1.2, 1.4) AM\*(1.3, 1.4)(1.4, 1.4) DM\*(1.5,1.4) ODM\*(0.9, 1.4) UDM\*ChiSQ0.0480.8540.7360.6460.6970.810.9090.973MAX30.0450.8680.7780.7040.7320.8180.9090.962GMS0.0440.8570.7680.6920.7240.810.9080.966CATT0.0440.7950.7870.7610.7240.7050.7010.815MERT0.0440.7890.7820.7630.7290.7180.7220.806GGM0.0450.8650.7950.7350.7460.8160.9010.962New0.0410.840.7730.7140.7470.8290.9190.952\**RM*: Recessive Model; *AM*: Additive Model; *DM*: Dominant Model; *ODM*: Over-dominant Model; *UDM*: Under-dominant Model.

Tables [5](#Tab5){ref-type="table"} and [6](#Tab6){ref-type="table"} report the empirical powers when HWE does not hold with the genotypic frequencies for controls are (0.1, 0.36, 0.54), and the disease risks are minor allele and major allele, respectively. Once again we can see that CATT and MERT are not robust; they may lose power dramatically under some conditions (e.g., over-dominant in Table [5](#Tab5){ref-type="table"} and under-dominant in Table [6](#Tab6){ref-type="table"}). The proposed test has comparable power values with those from the MAX3 and GMS; under some situations, it is more powerful (e.g., over-dominant model in Table [5](#Tab5){ref-type="table"}).Table 5**Empirical type I error rates and powers for each method from 1000 replicates at significance level 0.05 when the sample sizes are 1000 for cases and controls and the genotype frequencies for controls are (0.1,0.36,0.54) with minor allele is the disease allele*Λ*** ~1~ ***Λ*** ~2~(1,1)(1, 1.4) RM\*(1.1, 1.4)(1.2, 1.4) AM\*(1.3, 1.4)(1.4, 1.4) DM\*(1.5,1.4) ODM\*(0.9, 1.4) UDM\*ChiSQ0.0460.930.7430.5390.4260.4810.5650.995MAX30.040.9440.7710.6010.4730.4860.5070.995GMS0.040.9290.7560.6090.4710.490.5170.992CATT0.0430.9360.8070.6590.4590.3140.1940.974MERT0.0440.880.7630.6560.5170.4090.3020.933GGM0.0430.9520.7860.6350.4840.460.4370.995New0.0490.9260.7550.6160.4850.5140.5560.988\**RM*: Recessive Model; *AM*: Additive Model; *DM*: Dominant Model; *ODM*: Over-dominant Model; *UDM*: Under-dominant Model.Table 6**Empirical type I error rates and powers for each method from 1000 replicates at significance level 0.05 when the sample sizes are 1000 for cases and controls and the genotype frequencies for controls are (0.1,0.36,0.54) with major allele is the disease allele*Λ*** ~1~ ***Λ*** ~2~(1,1)(1, 1.4) RM\*(1.1, 1.4)(1.2, 1.4) AM\*(1.3, 1.4)(1.4, 1.4) DM\*(1.5,1.4) ODM\*(0.9, 1.4) UDM\*ChiSQ0.0420.550.5530.6730.8120.9270.9810.749MAX30.0440.5680.60.7180.8430.9390.9870.712GMS0.0410.5850.610.7180.820.9220.980.727CATT0.0410.4310.6070.7650.8540.9180.9620.248MERT0.0420.5120.6350.7550.8080.8660.8960.385GGM0.0360.550.6110.7430.8480.9420.9860.66New0.0430.5520.5970.7340.8490.9410.9810.654\**RM*: Recessive Model; *AM*: Additive Model; *DM*: Dominant Model; *ODM*: Over-dominant Model; *UDM*: Under-dominant Model.

The method based on GGM by Chen and Ng (GGM in Tables [2](#Tab2){ref-type="table"}--[6](#Tab6){ref-type="table"}) has similar performance as the proposed test. However, if the disease allele is the minor allele, the new test is more powerful than the GGM method when the genetic model is dominant or over-dominant (see Tables [2](#Tab2){ref-type="table"}, [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). In addition, unlike the proposed test, the GGM method doesn't report the disease allele.

Real data application {#Sec7}
---------------------

To illustrate the use of the proposed test, we apply it to some real data. The SNP rs181489 has been shown to be associated with Parkinson disease \[[@CR27]\]. Table [7](#Tab7){ref-type="table"} lists the genotypic counts of cases and controls of this SNP from fifteen sites \[[@CR27]\]. We apply the proposed test and others to the data of each site to obtain p-values. Table [8](#Tab8){ref-type="table"} reports the results along with the three statistics, z~1~, z~2~ and z~3~. Out of the 15 populations, 14 have positive values for z~3~, indicating the disease allele is A rather than G for this SNP. Recall the statistic z~1~ compares genotype GG to GA between controls and cases. A small z~1~ indicates the relative risk *Λ*~1~ is close to 1, and therefore the genetic model is close to the recessive one. On the other hand, if z~1~ is large, the underlying genetic model is unlikely to be a recessive model. For population D, the estimated z~1~ is -0.090, the genetic model is close to a recessive one, under which the CATT test is less powerful than other robust methods. In fact, for this population CATT obtains the largest p-value (0.024). Similar observation can be found for population G. In contrast, z~1~ and z~2~ from populations H and O are both large, indicating the underlying genetic models are close to the additive model, under which the CATT is more powerful than others. Therefore, there is no surprise that CATT obtains the smallest p-values from those two populations.Table 7**Genotypic count data for rs181489 from different populations (data obtained from**\[[@CR27]\]**)**PopulationCaseControlTotal nGGGAAAGGGAAAA: Australia40040299320307581586B: France2442455756111623C: Germany861191916187265D: Germany2221768513310725748E: Germany1441493916914029670F: Greece446717443710219G: Greece1191264713012318563H: Ireland1401475822915738769I: Italy78862187719352J: Italy73882844438284K: Italy33471041219161L: Norway29023380240228561127M: Poland1581444717113530685N: Sweden503010916817266O: USA1561705019113732736Table 8**P-values and Z statistics from different methods based on each population of the SNP rs181489 data**PopulationChiSQMAX3GMSCATTMERTNewZ1Z2Z3A: Australia0.230.190.200.140.110.160.441.661.72B: France0.660.640.470.410.380.510.340.840.90C: Germany0.200.180.510.460.310.230.54-1.70-1.41D: Germany0.0110.00600.00550.0240.0140.0088-0.0903.022.82E: Germany0.160.110.0890.0550.0580.0991.361.361.69F: Greece0.110.0800.120.0760.110.0822.020.511.19G: Greece0.00180.00110.00110.00320.00130.00120.633.513.52H: Ireland1.2e-45.8e-55.6e-52.2e-52.3e-57.0e-52.703.283.94I: Italy0.0550.0430.0360.0200.0160.0331.352.002.29J: Italy0.230.190.150.0980.0880.150.791.531.71K: Italy0.0130.0180.0150.0700.150.0122.94-0.310.63L: Norway0.180.340.250.940.730.43-1.311.330.86M: Poland0.120.100.0810.0490.0410.0770.881.882.05N: Sweden0.690.790.800.780.890.96-0.780.370.16O: USA0.00480.00310.00290.00130.00200.00262.661.902.61

Conclusions {#Sec8}
===========

Although CATT has been widely used in case--control GWAS with the assumption that the underlying genetic model is additive, its performance may be very poor if the true genetic model is not additive. Therefore, robust but powerful association tests are more appropriate when detecting the associated SNPs. Many existing association tests make the assumption that the genetic model is one of the three special genetic models (recessive, additive, and dominant), which may be a too strong assumption in practice. In this paper, we propose a robust association test without making strong assumption about the genetic model. Our simulation results show that even the assumption of GGM is violated (e.g., over- and under- dominant models), the proposed test still has reasonable power; indicating it is a robust test. In terms of computational cost, the proposed test is reasonably fast. For instance, it took my desktop about 70 seconds to get the results in Table [8](#Tab8){ref-type="table"} for the real data application. Our simulation study also confirmed that the proposed test can control type I error rate with smaller cutoff p-value, e.g., 10^-4^ and 10^-5^ (see Additional file [2](#MOESM2){ref-type="media"}: Table S1-S2).

The test statistic in (3) is defined based on the idea of combining p-values from independent studies using chi-square distribution with 1 degree of freedom \[[@CR26]\]. Although there are many other approaches available in the literature \[[@CR26], [@CR28]--[@CR31]\], it remains a research topic to choose the best one if there is any. However, it should be noticed that for case control GWAS, a robust method, such as the proposed test, is desirable due to the various underlying genetic models. In addition, when we combine the p-values from the 15 independent studies using the chi-square distribution with 1 degree of freedom \[[@CR26]\], the overall p-value is 2.6 × 10^-11^.

Through simulation studies and real data applications, we have shown that the proposed test is robust and powerful. In addition, the three statistics, z~1~, z~2~, and z~3~, may also provide useful information about the disease allele and the genetic model.
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